COPD News

News about the treatment and management of COPD, including current findings and information on promising new drugs.

Shortness of breath Donald Mahler Shortness of breath Donald Mahler

First Biologic Medicine - Dupixent - Approved for COPD

On September 27, 2024, the U. S. Food and Drug Administration (FDA) approved the first biologic medicine - dupilumab (brand name: Dupixent) - for the maintenance treatment of patients with COPD. The indication is for those with uncontrolled COPD and elevated eosinophils in the blood. Studies show a 30 to 34% reduction in COPD flare-ups over one year and an improvement in breathing tests. Dupilumab is injected under the skin every two weeks.

Read More
Shortness of breath Donald Mahler Shortness of breath Donald Mahler

New Nebulizer Medication -Ensifentrine - Approved for Treatment Of COPD

On June 26, 2024, the U. S. Food and Drug Administration approved a novel inhaled medication called ensifentrine (Ohtuvayre is the brand name) for the maintenance treatment of patients with COPD. This unique medication has both bronchodilator (opens airways) and anti-inflammatory properties and is delivered in a nebulizer twice a day.

Read More